IN2013MU02527A - - Google Patents

Info

Publication number
IN2013MU02527A
IN2013MU02527A IN2527MU2013A IN2013MU02527A IN 2013MU02527 A IN2013MU02527 A IN 2013MU02527A IN 2527MU2013 A IN2527MU2013 A IN 2527MU2013A IN 2013MU02527 A IN2013MU02527 A IN 2013MU02527A
Authority
IN
India
Prior art keywords
nucleotide sequence
insulin
leader peptide
sequence encoding
terminal end
Prior art date
Application number
Inventor
Sanjay Sonar
Archana Krishnan
Damodar Thappa
Original Assignee
Biogenomics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogenomics Ltd filed Critical Biogenomics Ltd
Priority to IN2527MU2013 priority Critical patent/IN2013MU02527A/en
Priority to SG11201600684XA priority patent/SG11201600684XA/en
Priority to PCT/IN2014/000506 priority patent/WO2015015518A2/en
Priority to US14/908,854 priority patent/US10000544B2/en
Priority to EP14789420.8A priority patent/EP3027645A2/en
Publication of IN2013MU02527A publication Critical patent/IN2013MU02527A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A process for production of insulin or insulin analogues by expression of Insulin or Insulin analogues through an expression vector in a host cell is provided. The expression vector includes a leader peptide of SEQ ID NO 3; a nucleotide sequence encoding an affinity tag linked to C-terminal end or N terminal end of nucleotide sequence of the leader peptide; and a nucleotide sequence encoding for a cleavage site ligated to nucleotide sequence of the leader peptide through nucleotide sequence encoding the affinity tag.
IN2527MU2013 2013-07-31 2014-07-31 IN2013MU02527A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
IN2527MU2013 IN2013MU02527A (en) 2013-07-31 2014-07-31
SG11201600684XA SG11201600684XA (en) 2013-07-31 2014-07-31 Process for production of insulin and insulin analogues
PCT/IN2014/000506 WO2015015518A2 (en) 2013-07-31 2014-07-31 Process for production of insulin and insulin analogues
US14/908,854 US10000544B2 (en) 2013-07-31 2014-07-31 Process for production of insulin and insulin analogues
EP14789420.8A EP3027645A2 (en) 2013-07-31 2014-07-31 Process for production of insulin and insulin analogues

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN2527MU2013 IN2013MU02527A (en) 2013-07-31 2014-07-31

Publications (1)

Publication Number Publication Date
IN2013MU02527A true IN2013MU02527A (en) 2015-06-26

Family

ID=51794935

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2527MU2013 IN2013MU02527A (en) 2013-07-31 2014-07-31

Country Status (5)

Country Link
US (1) US10000544B2 (en)
EP (1) EP3027645A2 (en)
IN (1) IN2013MU02527A (en)
SG (1) SG11201600684XA (en)
WO (1) WO2015015518A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115716876A (en) * 2022-07-04 2023-02-28 北京惠之衡生物科技有限公司 Fusion protein and application thereof

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9803207B2 (en) 2013-07-31 2017-10-31 Biogenomics Limited Expression vector for production of recombinant proteins in prokaryotic host cells
JP2020529221A (en) * 2017-07-28 2020-10-08 ザ・トラスティーズ・オブ・プリンストン・ユニバーシティＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｐｒｉｎｃｅｔｏｎ Ｕｎｉｖｅｒｓｉｔｙ Fusion tag for recombinant protein expression
EP3807306A4 (en) * 2018-06-18 2022-04-06 Unichem Laboratories Limited Leader sequence for higher expression of recombinant proteins
CN112584853B (en) * 2018-09-12 2021-12-10 美药星（南京）制药有限公司 Structure of novel insulin aspart and method for preparing insulin aspart
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004085472A1 (en) * 2003-03-27 2004-10-07 Novo Nordisk A/S Method for making human insulin precursors and human insulin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115716876A (en) * 2022-07-04 2023-02-28 北京惠之衡生物科技有限公司 Fusion protein and application thereof

Also Published As

Publication number Publication date
US20160168226A1 (en) 2016-06-16
EP3027645A2 (en) 2016-06-08
WO2015015518A3 (en) 2015-04-16
US10000544B2 (en) 2018-06-19
WO2015015518A2 (en) 2015-02-05
SG11201600684XA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
IN2013MU02527A (en)
MX2018016114A (en) Novel heat-resistant fructose-6-phosphate-3-epimerase and method for producing allulose by using same.
MX2017006866A (en) Fusion partners for peptide production.
NZ628446A (en) Fibronectin based scaffold domain proteins that bind to myostatin
NZ712168A (en) Synthetic brassica-derived chloroplast transit peptides
NZ707439A (en) Modified factor ix polypeptides and uses thereof
CR20200234A (en) Polypeptide for the hydrolytic cleavage of zearalenone and/or zearalenone derivatives, isolated polynucleotide thereof, and additive containing polypeptide, use of said polypeptide and method
IN2014KN02823A (en)
WO2014202622A3 (en) Rasamsonia gene and use thereof
AU2010255732A8 (en) Recombinant production of peptides
EA033437B1 (en) Fc GAMMA RECEPTOR IIB AND USE THEREOF FOR TREATING OR PREVENTING INFLAMMATORY AND/OR AUTOIMMUNE DISEASES
MY180953A (en) Acyl-acp thioesterase
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
NZ604412A (en) Vaccine and methods to reduce campylobacter infection
MX2017010359A (en) Fc-FUSED HIGH AFFINITY IgE RECEPTOR a-CHAIN.
NZ586074A (en) LCLRP peptides, constructs and uses thereof
MY184387A (en) Improved surface display of functional proteins in a broad range of gram negative bacteria
IN2014DN09367A (en)
BR112016000553A2 (en) Reed roux ACP thioesterase
MX2016007407A (en) Protease resistant peptides.
PE20211303A1 (en) POLYPEPTIDES OF SHORT ACTION FACTOR VII
AR119056A2 (en) FUSION PEPTIDE, ENCODING POLYNUCLEOTIDE, VECTOR AND TRANSFORMED CELL
MX2013012986A (en) Plants having one or more enhanced yield- related traits and method for making the same.
IN2013MU02526A (en)